AUD

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Retrieved on: 
Wednesday, April 3, 2024
Randomized controlled trial, Psilocybin, Safety, JAMA Psychiatry, Medicine, Marketing, Clinical trial, CMA

Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe.

Key Points: 
  • Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe.
  • A top line read out from the clinical trial is expected in Q3 2024 and a Series A financing round is currently underway.
  • "We are quickly approaching a critical and exciting moment for psilocybin and its potential use as a recognized treatment," said Damian Kettlewell, CEO, Clairvoyant.
  • Clairvoyant intends to launch a pivotal confirmatory trial in H2 2025, with a read out in 2027, to support full approval of psilocybin treatment in Canada, the EU and UK.

Asphalt Innovators MR-Roads Eye National Expansion After Successful First Year

Retrieved on: 
Monday, May 6, 2024
Workforce, BP, Construction, Investment, Growth, Transport

The Queensland-based firm plans to extend its services to key regions across Australia, including New South Wales, Victoria, and South Australia.

Key Points: 
  • The Queensland-based firm plans to extend its services to key regions across Australia, including New South Wales, Victoria, and South Australia.
  • This move comes after MR-Roads surpassed AUD 12 million in revenue and executed several high-profile projects.
  • They also completed a substantial carpark in Southport and carried out extensive asphalt work for multiple BP service stations.
  • Establishing new offices and increasing its presence in strategic locations will support its national expansion, from local government infrastructure to large commercial developments.

AM Best Affirms Credit Ratings of Guild Insurance Limited

Retrieved on: 
Thursday, May 9, 2024
Insurance, Professional Services, Weather, News, Credit, AM Best, Communication, Risk management, GIL, ALL, Pharmacy

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Guild Insurance Limited (GIL) (Australia).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Guild Insurance Limited (GIL) (Australia).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry.

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Retrieved on: 
Monday, April 22, 2024
Opioid use disorder, OUD, GLEN, Obesity, Addiction, Patent, Patient, Alcohol, Pharmaceutical industry

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.

Key Points: 
  • GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.
  • Cary Claiborne, CEO of Adial, commented, “We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies.
  • Importantly, we have identified specific genotypes that have responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, which represents an addressable market of approximately $40 billion in the U.S. alone.
  • We believe our unique personalized approach can offer new hope to the millions affected by AUD, OUD and other addictive disorders such as obesity and gambling.”

Vast Executes VS1 Engineering Contracts Advancing Toward Construction of 288 MWh Concentrated Solar Thermal Power Plant

Retrieved on: 
Monday, April 15, 2024
Primero, Carbon, Electricity, VS1, Engineering, Kilowatt-hour, CSP, FEED, ARENA, SM1, Government, Renewable energy

VS1 is a 30MW / 288 MWh CSP plant to be located in Port Augusta, South Australia.

Key Points: 
  • VS1 is a 30MW / 288 MWh CSP plant to be located in Port Augusta, South Australia.
  • Utilising Vast’s proprietary modular tower CSP v3.0 technology, VS1 will generate clean, low-cost, dispatchable power with over 8 hours of thermal energy storage.
  • The project is anticipated to create dozens of green manufacturing jobs, hundreds of jobs during construction and long-term plant operations roles.
  • Craig Wood, CEO of Vast said, "This is a major step forward for Vast and VS1, putting this historic CSP project on the path to construction.

Locafy Announces New Value-Based SEO Pricing Model

Retrieved on: 
Thursday, April 11, 2024
PPC, Directory, Keystone, Marketing, Advertising

PERTH, Australia, April 11, 2024 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in programmatic “Entity-Based” search engine marketing, today announced that it has released an SEO product with a new value-based pricing model that it anticipates will drive a strong increase in recurring subscription revenues. The Company believes that this model is the first of its kind in the automated SEO industry.

Key Points: 
  • The Company believes that this model is the first of its kind in the automated SEO industry.
  • “In digital marketing, the core objective is to drive visitors to a client’s website, typically measured in ‘clicks,’” said Locafy CEO Gavin Burnett.
  • “We believe that this pricing model will resonate with digital agencies and business owners that have traditionally been skeptical of SEO services, as we’re removing the financial risk from SEO campaigns and providing certainty in SEO spending return on investment.
  • Under Locafy’s new performance-based pricing model, an identical paying client could be expected to generate around a 50% increase in revenue for Locafy.

Immuron Travelan® sales continued strong growth

Retrieved on: 
Wednesday, April 10, 2024
Statistics, Immuron, ASX, Growth, Walmart, IMC

MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Key Points: 
  • Sales of Travelan® increased 250% to AUD $2.7 million FYTD Mar 2024 compared to AUD $0.8 million FYTD Mar 2023.
  • Sales of Travelan® increased 70% to AUD $0.9 million Mar 2024 Quarter compared to AUD $0.5 million Mar 2023 Quarter.
  • Sales of Travelan® increased 7% to AUD $0.3 million Mar 2024 Quarter compared to AUD $0.3 million Mar 2023 Quarter.
  • Immuron’s investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia.

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Retrieved on: 
Wednesday, April 10, 2024
Liver injury, Safety, GLEN, Epistasis, ALT, Patient, European Journal, Liver, ALD, GGT, Annals of Internal Medicine, Aes, Manuscript, Internal medicine, Liver transplantation, Open access

According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.

Key Points: 
  • According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.
  • Additionally, while patients with AUD displayed elevated GGT levels, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04.
  • This peer-reviewed publication emphasizes the safety and potential of AD04 in addressing the critical needs of individuals suffering from AUD and ALD.
  • Most importantly, the publication highlighted the potential of AD04 for the treatment for AUD among patients with a specified genetic background.

Lazard Reports First-Quarter 2024 Results

Retrieved on: 
Thursday, April 25, 2024
Professional Services, Finance, Debt-to-GDP ratio, Sale, Avison Young, Service provider, Schaeffler Group, Enviva, Vitesco Technologies, Weather, CSR Limited, Lazard, AbbVie, Thomson Reuters, Francisco Partners, SVB, The Weather Company, Conference, Euronext Paris, Rubicon, Mars, Endo International, Tax, Silicon, Lumen Technologies, AUM, Acquisition, Mars, Incorporated, Massimo Zanetti Beverage Group, AFE, Share repurchase, Bank statement, Name, Asset management, GAAP, Sixth Street Partners, Note, Telescopic sight

On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.

Key Points: 
  • On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.
  • Beginning in the first quarter of 2024, Lazard has updated the names of certain non-U.S. GAAP ("non-GAAP") measures and metrics.
  • We believe that presenting our results on an adjusted basis, in addition to the U.S. GAAP results, is a meaningful and useful way to compare our operating results across periods.
  • ET on April 25, 2024, to discuss the company’s financial results for the first quarter of 2024.

Tillo Announces Market Leading FX Capabilities to Streamline International Trading Experience

Retrieved on: 
Wednesday, April 24, 2024
RON, GBP, System, Automation, PLN, EUR, DKK, CAD, CHF, NOK, FX, HUF, Online shopping

BRIGHTON, United Kingdom and AUSTIN, Texas, April 24, 2024 /PRNewswire-PRWeb/ --Tillo, the embedded rewards and incentives platform, has announced International Payments, a new and innovative feature of the Tillo Platform and the first of its kind, which eliminates the need for global gift card buyers to maintain separate currency floats.

Key Points: 
  • This new feature enables buyers to seamlessly execute FX transactions while purchasing gift cards, providing a simple, cost-effective, and efficient international trading experience.
  • Recognizing the varied needs of global customers, the International Payments feature was created to streamline this process.
  • Key benefits of International Payments include:
    Automation: Unlike other platforms on the market, Tillo's International Payments removes the need for any manual conversion, as FX rates are applied automatically during the purchase process.
  • Cost-effectiveness: With the International Payments feature, buyers can avoid additional fees from third-party FX platforms.